Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing - 05/31/2019 - 05/31/2019
- May 31, 2019
- May 31, 2019
Event LocationWhite Oak Campus: The Great Room
The Great Room
10903 New Hampshire Ave
Bldg 31 Conference Center, The Great Room (Rm 1503)
Silver Spring, MD 20993
- Organized By:
FDA Campus Information (e.g., local airports, directions, and local hotels)
As stated in the Federal Register notice, requests to attend the hearing in person and/or to make a presentation/provide oral comments during the hearing must be received by May 10th. Due to space and time limitations, it is possible that not all requests can be accommodated. Therefore, registering on this site does not guarantee in person attendance and/or a time slot to make a presentation/provide oral comments. Your confirmation to attend the hearing in person and/or to make a presentation/provide oral comments will be provided by May 21, 2019. Registrants can also view the hearing via webcast. All meeting attendees and other interested parties may submit information to the public docket FDA-2019-N-1482.
The Food and Drug Administration is announcing a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. See the Federal Register notice for more information.
FDA will webcast this public hearing. Click here to view the hearing via webcast. Barring any technical difficulties, FDA plans to post a link to the recorded webcast after the hearing.
FDA is establishing a docket for public comment on this hearing. The docket number is FDA-2019-N-1482. The docket will close on July 2, 2019. Submit either electronic or written comments on this public hearing by July 2, 2019. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 2, 2019. The Regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 2, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852